Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.50 |
| ▸ | ICMT | O60725 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19597086 | 0.89 | ADORA2A (0.65) | ADORA2AADORA2BKDM4CICMTGLS | |
| SCHEMBL19597232 | 0.87 | ADORA2A (0.43) | ADORA2AADORA2BKDM4CICMTCNR2 | |
| SCHEMBL19597097 | 0.85 | KDM4C (0.52) | ADORA2AADORA2BKDM4CGLS | |
| SCHEMBL15792217 | 0.84 | KDM4C (0.49) | KDM4CICMTCNR2CNR1ACHE | |
| SCHEMBL19596937 | 0.83 | KDM4C (0.40) | ADORA2AADORA2BKDM4CICMTGLS | |
| SCHEMBL19597358 | 0.83 | KDM4C (0.53) | ADORA2AADORA2BKDM4CICMTGLS | |
| SCHEMBL19597374 | 0.83 | ADORA2A (0.42) | ADORA2AADORA2BKDM4CCNR2CNR1 | |
| SCHEMBL17232744 | 0.83 | ADORA2A (0.62) | ADORA2AADORA2BKDM4CGLSALDH1A1 | |
| SCHEMBL19596954 | 0.82 | ADORA2A (0.46) | ADORA2AADORA2BKDM4CGLSALDH1A1 | |
| SCHEMBL18723313 | 0.78 | MPO (0.47) | KDM4CICMTCNR2CNR1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040779-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170174656-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040779-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM5C | ADORA2A 2772/4885ADORA2B 2892/4885KDM4C 13/4885 |
| US-20170174656-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM5C | ADORA2A 2772/4885ADORA2B 2892/4885KDM4C 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.